ASAM Weekly for November 29, 2022
This Week in the ASAM Weekly
Dr. Nora Volkow, director of the National Institute on Drug Abuse, recently advocated for broadening access to methadone treatment for OUD (STAT News). While some politicians or trade groups may frame this as radical, such leading-expert opinion is based on scientific evidence and an appreciation for a rapidly evolving addiction crisis. As the lead article demonstrates, the increasing co-use of stimulants and opioids has significantly increased the risk for overdose death, and the possible reasons tell only part of the story: discontinuation of opioid agonist treatment, lack of similar medications for stimulants, potency of illicit drug supply, etc…(BMC Public Health).
Scientific and political innovation will help us catch up to the crisis. A promising vaccine demonstrated efficacy in both male and female rats to several physiological properties of fentanyl without blocking effects of other opioids (Pharmaceutics). Future direction in depression treatment may involve a better understanding of the opioid system (Biological Psychiatry).And Italy has developed a system of wastewater-based epidemiology that could better prepare us for future trends in the use of major and new psychoactive substances (La Clinica Terapeutica).
Dr. Volkow has also been advocating to update the institute’s name to the National Institute of Drugs and Addiction. Such choice words will speak volumes and such action will inspire others, but such change may take an act of Congress (STAT News).
Thanks for reading,
Nicholas Athanasiou, MD, MBA, DFASAM
Editor in Chief
with Co-Editors: Brandon Aden, MD, Debra R. Newman, PA-C, MSPAS, MPH, Jack Woodside, MD, John A. Fromson, MD
Lead Story
Concurrent use of opioids and stimulants and risk of fatal overdose: A cohort study 🔓
BMC Public Health
The authors note a dramatic increase in the use of methamphetamine in people with OUD and an increased presence of a stimulant in opioid toxicity deaths. A random sample of 20% of persons in the overdose registry of the Province of British Columbia, Canada, was selected for years 2010 to 2018. Persons who used opioids, stimulants, or both (n=7460) were identified by ICD codes and fatal overdose events determined from coroners’ data. People using both opioids and stimulants had twice the risk of fatal overdose compared to those using opioids only (HR=2.02, p<0.001). People using stimulants alone had a similar risk of fatal overdose to those using opioids alone (HR=1.05, p=0.76). The authors note that while concern has been directed toward the opioid crisis, people who use stimulants have a similar risk of fatal overdose. They call for increased support for people who use stimulants.
Call for Reviewers
The Journal of Addiction Medicine is seeking to expand its cadre of manuscript reviewers. We are seeking reviewers with expertise in the following areas: Stimulants, Psychiatric epidemiology, Qualitative methodology, Genetics, Neurology, Emerging substances, Kratom, Novel Psychoactive Substances, Psychedelics, New pharmaceutical treatments, Toxicology, Criminal justice and addiction medicine, Machine Learning, Pain and Palliative Care, Adolescent Medicine, Maternal Child Health, and Behavioral Addictions. View the full opportunity here.
Research and Science
The Lancet Psychiatry
This retrospective cohort study investigated the risk of all-cause death and years lost following hospitalization in people with a previous hospitalization for a substance use disorder (SUD). Using Czech national health registries, individuals with a SUD had an increased risk of death due to any cause after the onset of 26 out of 28 physical health conditions, in comparison to those without a SUD. Individuals with SUDs had substantial years lost after the onset of physical health conditions; in most cases, considerably larger losses than those without SUDs.
Pharmaceutics
Fentanyl (FEN) is a potent synthetic opioid associated with increasing incidence of opioid use disorder (OUD) and fatal opioid overdose. Vaccine immunotherapy for FEN-associated disorders may be a viable therapeutic strategy. In this study, immunized male and female rats produced significant levels of anti-FEN antibodies that were highly effective at neutralizing FEN–induced antinociception in the tail flick assay and hot plate assays. The vaccine also decreased FEN brain levels following drug administration. Immunization blocked FEN-induced, but not morphine-induced, rate-disrupting effects on schedule-controlled responding. Cross-reactivity assays showed anti-FEN antibodies bound to FEN and sufentanil but not to morphine, methadone, buprenorphine, or oxycodone. These data support further clinical development of this vaccine to address OUD in humans.
Substance Use and Misuse
While opioid use disorder (OUD) among adolescents has increased, they are less likely to access treatment, particularly medications for opioid use disorders (MOUD). In this paper, the authors interviewed prescribers and non-prescribers who attended a learning series focused on treatment of adolescents to assess perceptions on providing MOUD to adolescents. While prescribers were overwhelmingly supportive of providing MOUD to adolescents, including those under the age 18, non-prescribers were less likely to support MOUD for adolescents, particularly those under 18. Major barriers reported were lack of training and experience and increases in social work and mental health services were needed to increase access.
Learn More
Take-home Naloxone at Opioid Treatment Programs: A Lifesaver 🔓
Journal of Addiction Medicine
In this commentary, the authors propose take-home naloxone (THN) and overdose education at all federally-qualified opioid treatment programs (OTPs). Broadening the reach, patients enrolled at an OTP can educate their social network about its benefits. Should mandating THN at OTPs be successful, the practice could be considered for anyone leaving a federal correctional facility with a diagnosis of an OUD. From a public health perspective, THN may also encourage people who misuse opioids, including those who have been reversed by naloxone, to engage in treatment.
Wastewater analysis and drug consumption: useful assessment tool 🔓
La Clinica Terapeutica
Drug use epidemiology has been based on questionnaires where accuracy is subject to sampling bias and subjects’ truthfulness. This letter describes the use of wastewater screening for drug metabolites used in 33 cities in Italy to monitor the epidemiology of drug use. Results are expressed as doses per 1000 inhabitants based on the size of a typical dose and knowledge of its metabolism. Results show trends of increase or decrease in the use of specific substances over time. Also, the mix of substances differs from city to city. In addition, 69 new psychoactive substances were identified. They conclude that this is a valuable tool for tracking patterns of drug use and trafficking.
Addictive Behaviors
While operant conditioning is a well-studied etiology of excessive gambling, the authors argue that a more complex motivation exists. Current models do not account for people’s perceptions of contingency and the relationship between their behavior and outcomes. In addition, people can modify schedules of rewards to which they are exposed, particularly on slot machines, by choosing the number of lines and amounts of bets. There are short and long-term schedule-based rewards that may influence behavior. Finally, there is a potential role for negative reinforcement, specifically regret or anticipated regret about not placing a bet. Research is needed to better understand this complex behavior and to inform future interventions and policies.
Opioid Systems and Depression: The Relationship Is Strengthening
Biological Psychiatry
This commentary examines the findings of Carazo-Arias et al.* As antidepressant treatments evolve, it is likely that the opioid systems will become one of the core modulatory systems to target, either directly using mu opioid receptors (MORs), delta opioid receptors (DORs), kappa opioid receptors (KOR), or indirectly via SSRIs or tricyclic antidepressants. Depression can undoubtedly have many different etiologies and will require different pharmacotherapies. Future research will need to assess if fluoxetine efficacy always requires endogenous opioid systems for alleviating negative affective states.
*Contribution of the opioid system to the antidepressant effects of fluoxetine. Biol Psychiatry 2022
New Articles Available for CME in ASAM's eLearning Center
In The News
Dr. Mitchell Rosenthal, Phoenix House Founder, Dies at 87
New York Times
Cigars, Booze, Money: How a Lobbying Blitz Made Sports Betting Ubiquitous
New York Times
Despite data on drinking’s harm, little action at New Mexico Health Department
Santa Fe New Mexican
Top U.S. addiction researcher calls for broad deregulation of methadone
Stat News
Schools, Sheriffs, and Syringes: State Plans Vary for Spending $26B in Opioid Settlement Funds
Kaiser Health News
State AGs Urge Continued Virtual Care Access for Opioid Use Disorder Treatment
mHealth Intelligence
Minnesota health officials weigh whether to allow medical cannabis for opioid use disorder
MinnPost
Recent and Past Issues
ASAM Weekly for November 29, 2022
This Week in the ASAM Weekly
Dr. Nora Volkow, director of the National Institute on Drug Abuse, recently advocated for broadening access to methadone treatment for OUD (STAT News). While some politicians or trade groups may frame this as radical, such leading-expert opinion is based on scientific evidence and an appreciation for a rapidly evolving addiction crisis. As the lead article demonstrates, the increasing co-use of stimulants and opioids has significantly increased the risk for overdose death, and the possible reasons tell only part of the story: discontinuation of opioid agonist treatment, lack of similar medications for stimulants, potency of illicit drug supply, etc…(BMC Public Health).
Scientific and political innovation will help us catch up to the crisis. A promising vaccine demonstrated efficacy in both male and female rats to several physiological properties of fentanyl without blocking effects of other opioids (Pharmaceutics). Future direction in depression treatment may involve a better understanding of the opioid system (Biological Psychiatry).And Italy has developed a system of wastewater-based epidemiology that could better prepare us for future trends in the use of major and new psychoactive substances (La Clinica Terapeutica).
Dr. Volkow has also been advocating to update the institute’s name to the National Institute of Drugs and Addiction. Such choice words will speak volumes and such action will inspire others, but such change may take an act of Congress (STAT News).
Thanks for reading,
Nicholas Athanasiou, MD, MBA, DFASAM
Editor in Chief
with Co-Editors: Brandon Aden, MD, Debra R. Newman, PA-C, MSPAS, MPH, Jack Woodside, MD, John A. Fromson, MD
Lead Story
Concurrent use of opioids and stimulants and risk of fatal overdose: A cohort study 🔓
BMC Public Health
The authors note a dramatic increase in the use of methamphetamine in people with OUD and an increased presence of a stimulant in opioid toxicity deaths. A random sample of 20% of persons in the overdose registry of the Province of British Columbia, Canada, was selected for years 2010 to 2018. Persons who used opioids, stimulants, or both (n=7460) were identified by ICD codes and fatal overdose events determined from coroners’ data. People using both opioids and stimulants had twice the risk of fatal overdose compared to those using opioids only (HR=2.02, p<0.001). People using stimulants alone had a similar risk of fatal overdose to those using opioids alone (HR=1.05, p=0.76). The authors note that while concern has been directed toward the opioid crisis, people who use stimulants have a similar risk of fatal overdose. They call for increased support for people who use stimulants.
Call for Reviewers
The Journal of Addiction Medicine is seeking to expand its cadre of manuscript reviewers. We are seeking reviewers with expertise in the following areas: Stimulants, Psychiatric epidemiology, Qualitative methodology, Genetics, Neurology, Emerging substances, Kratom, Novel Psychoactive Substances, Psychedelics, New pharmaceutical treatments, Toxicology, Criminal justice and addiction medicine, Machine Learning, Pain and Palliative Care, Adolescent Medicine, Maternal Child Health, and Behavioral Addictions. View the full opportunity here.
Research and Science
The Lancet Psychiatry
This retrospective cohort study investigated the risk of all-cause death and years lost following hospitalization in people with a previous hospitalization for a substance use disorder (SUD). Using Czech national health registries, individuals with a SUD had an increased risk of death due to any cause after the onset of 26 out of 28 physical health conditions, in comparison to those without a SUD. Individuals with SUDs had substantial years lost after the onset of physical health conditions; in most cases, considerably larger losses than those without SUDs.
Pharmaceutics
Fentanyl (FEN) is a potent synthetic opioid associated with increasing incidence of opioid use disorder (OUD) and fatal opioid overdose. Vaccine immunotherapy for FEN-associated disorders may be a viable therapeutic strategy. In this study, immunized male and female rats produced significant levels of anti-FEN antibodies that were highly effective at neutralizing FEN–induced antinociception in the tail flick assay and hot plate assays. The vaccine also decreased FEN brain levels following drug administration. Immunization blocked FEN-induced, but not morphine-induced, rate-disrupting effects on schedule-controlled responding. Cross-reactivity assays showed anti-FEN antibodies bound to FEN and sufentanil but not to morphine, methadone, buprenorphine, or oxycodone. These data support further clinical development of this vaccine to address OUD in humans.
Substance Use and Misuse
While opioid use disorder (OUD) among adolescents has increased, they are less likely to access treatment, particularly medications for opioid use disorders (MOUD). In this paper, the authors interviewed prescribers and non-prescribers who attended a learning series focused on treatment of adolescents to assess perceptions on providing MOUD to adolescents. While prescribers were overwhelmingly supportive of providing MOUD to adolescents, including those under the age 18, non-prescribers were less likely to support MOUD for adolescents, particularly those under 18. Major barriers reported were lack of training and experience and increases in social work and mental health services were needed to increase access.
Learn More
Take-home Naloxone at Opioid Treatment Programs: A Lifesaver 🔓
Journal of Addiction Medicine
In this commentary, the authors propose take-home naloxone (THN) and overdose education at all federally-qualified opioid treatment programs (OTPs). Broadening the reach, patients enrolled at an OTP can educate their social network about its benefits. Should mandating THN at OTPs be successful, the practice could be considered for anyone leaving a federal correctional facility with a diagnosis of an OUD. From a public health perspective, THN may also encourage people who misuse opioids, including those who have been reversed by naloxone, to engage in treatment.
Wastewater analysis and drug consumption: useful assessment tool 🔓
La Clinica Terapeutica
Drug use epidemiology has been based on questionnaires where accuracy is subject to sampling bias and subjects’ truthfulness. This letter describes the use of wastewater screening for drug metabolites used in 33 cities in Italy to monitor the epidemiology of drug use. Results are expressed as doses per 1000 inhabitants based on the size of a typical dose and knowledge of its metabolism. Results show trends of increase or decrease in the use of specific substances over time. Also, the mix of substances differs from city to city. In addition, 69 new psychoactive substances were identified. They conclude that this is a valuable tool for tracking patterns of drug use and trafficking.
Addictive Behaviors
While operant conditioning is a well-studied etiology of excessive gambling, the authors argue that a more complex motivation exists. Current models do not account for people’s perceptions of contingency and the relationship between their behavior and outcomes. In addition, people can modify schedules of rewards to which they are exposed, particularly on slot machines, by choosing the number of lines and amounts of bets. There are short and long-term schedule-based rewards that may influence behavior. Finally, there is a potential role for negative reinforcement, specifically regret or anticipated regret about not placing a bet. Research is needed to better understand this complex behavior and to inform future interventions and policies.
Opioid Systems and Depression: The Relationship Is Strengthening
Biological Psychiatry
This commentary examines the findings of Carazo-Arias et al.* As antidepressant treatments evolve, it is likely that the opioid systems will become one of the core modulatory systems to target, either directly using mu opioid receptors (MORs), delta opioid receptors (DORs), kappa opioid receptors (KOR), or indirectly via SSRIs or tricyclic antidepressants. Depression can undoubtedly have many different etiologies and will require different pharmacotherapies. Future research will need to assess if fluoxetine efficacy always requires endogenous opioid systems for alleviating negative affective states.
*Contribution of the opioid system to the antidepressant effects of fluoxetine. Biol Psychiatry 2022
New Articles Available for CME in ASAM's eLearning Center
In The News
Dr. Mitchell Rosenthal, Phoenix House Founder, Dies at 87
New York Times
Cigars, Booze, Money: How a Lobbying Blitz Made Sports Betting Ubiquitous
New York Times
Despite data on drinking’s harm, little action at New Mexico Health Department
Santa Fe New Mexican
Top U.S. addiction researcher calls for broad deregulation of methadone
Stat News
Schools, Sheriffs, and Syringes: State Plans Vary for Spending $26B in Opioid Settlement Funds
Kaiser Health News
State AGs Urge Continued Virtual Care Access for Opioid Use Disorder Treatment
mHealth Intelligence
Minnesota health officials weigh whether to allow medical cannabis for opioid use disorder
MinnPost
This Week in Addiction Medicine Podcast
A weekly audio summary and podcast of the ASAM Weekly
The ASAM Weekly
Editors & Staff
Editor-in-Chief: Nicholas Athanasiou, MD, MBA, DFASAM
Emeritus Editor: William Haning, MD, DFAPA, DFASAM
Publications Chair: Nicholas Athanasiou, MD, MBA, DFASAM
Co-Editors: Brandon
Aden, MD, Debra R. Newman, PA-C, MSPAS, MPH, Jack Woodside, MD, John A. Fromson, MD
Please direct customer service inquiries and comments to: ASAMWeekly@ASAM.org
The ASAM Weekly
Advertiser Services & Sales
Ad space is limited and available on a first-paid, first-published basis. To assure your ad will run in the specific issue you select, Insertion Orders must be signed by an authorized person in your organization and accepted by your customer service representative before taking the advertising units out of the active sales inventory. Payment must be received prior to the run date for an ad. Insertion Orders provide several options for payment in full including all major credit cards or check. Pre-approved billing must be arranged directly by an ASAM representative.
To learn more about advertising opportunities
Contact: Bob Davis at Bdavis@ASAM.org
Leave a comment